193 related articles for article (PubMed ID: 25344862)
21. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.
Sharon C; Baranwal S; Patel NJ; Rodriguez-Agudo D; Pandak WM; Majumdar AP; Krystal G; Patel BB
Oncotarget; 2015 Jun; 6(17):15332-47. PubMed ID: 25895029
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
[TBL] [Abstract][Full Text] [Related]
24. Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer.
Huang EC; Chen G; Baek SJ; McEntee MF; Collier JJ; Minkin S; Biggerstaff J; Whelan J
Nutr Cancer; 2011 Nov; 63(8):1287-96. PubMed ID: 21958043
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
26. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
Cardillo TM; Trisal P; Arrojo R; Goldenberg DM; Chang CH
BMC Cancer; 2013 Apr; 13():170. PubMed ID: 23548153
[TBL] [Abstract][Full Text] [Related]
27. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
[TBL] [Abstract][Full Text] [Related]
28. Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells.
Li P; Veldwijk MR; Zhang Q; Li ZB; Xu WC; Fu S
BMC Cancer; 2013 Jun; 13():297. PubMed ID: 23777562
[TBL] [Abstract][Full Text] [Related]
29. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
30. The novel IGF-IR/Akt-dependent anticancer activities of glucosamine.
Song KH; Kang JH; Woo JK; Nam JS; Min HY; Lee HY; Kim SY; Oh SH
BMC Cancer; 2014 Jan; 14():31. PubMed ID: 24438088
[TBL] [Abstract][Full Text] [Related]
31. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
32. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
[TBL] [Abstract][Full Text] [Related]
33. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
[TBL] [Abstract][Full Text] [Related]
34. Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.
Chen LH; Fang J; Sun Z; Li H; Wu Y; Demark-Wahnefried W; Lin X
J Nutr; 2009 Apr; 139(4):653-9. PubMed ID: 19211828
[TBL] [Abstract][Full Text] [Related]
35. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
36. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
37. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
38. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
39. AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways.
Mendivil A; Zhou C; Cantrell LA; Gehrig PA; Malloy KM; Blok LJ; Burger CW; Bae-Jump VL
Reprod Sci; 2011 Sep; 18(9):832-41. PubMed ID: 21846689
[TBL] [Abstract][Full Text] [Related]
40.
Hu X; Zheng W; Luo Y; Ou X; Song L; Zhang S; He T; Guo Z; Zhu J; Shi H; Huang W; Yu R
Nutr Cancer; 2020; 72(2):260-272. PubMed ID: 31295033
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
